🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

$REPL will be presenting at #SITC22 on November 10th and 11th – we hope to see you there.

Looking forward to present! Oncolytic immunotherapy #biomarkers and#SITC22

Nice treat for Journal for ImmunoTherapy of Cancer readers! Neoadj CSCC Neil D. Gross, MD, FACS , Seq of aPD-1 and BRAF/MEKi in melanoma Dr. Atkins Georgetown Lombardi, Harmonal therapies in females overcome ICB myocarditis Chunrulin MD Anderson Cancer Center , Oncometabolite D-2HG impairs T cell function Giulia Notarangelo Harvard Medical School

$REPL announces positive interim snapshot data from its registration-directed IGNYTE clinical trial cohort in anti-PD1 failed cutaneous melanoma and provides a program update on RP2 and RP3: ir.replimune.com/news-releases/…

36% ORR in n=75 advanced melanoma pt who failed anti-PD-1+/-aCTLA-4. Responses observed across all subgroups of pt. Very well tolerated!!

36% ORR and 20% CR rates in n=75 advanced melanoma pt who failed anti-PD-1+/-aCTLA-4. Responses are durable and observed across all subgroups, further RP1+nivo is very well tolerated!! ir.replimune.com/news-releases/…

Nice interview by Brad Loncar Robert Coffin about the development of next generation potent oncolytic immunotherapies

New #JITC article: Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer bit.ly/46OqtqP Sachin Jhawar Praveen Bommareddy Howard Kaufman Andrew Zloza, MD, PhD

Final (five year) results for neoadjuvant T-VEC + surgery vs surgery alone in resectable advanced melanoma shows pronounced improvements with T-VEC for all outcomes, including OS jamanetwork.com/journals/jamao…

New #JITC article: Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG bit.ly/3PoapV6 Max Haist

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy: brilliant review from Suzanne Topalian and Drew Pardoll et al. ⁦Cancer Cell⁩ cell.com/cancer-cell/fu…

Hi everyone, my lab at Icahn Genomics Institute and Lipschultz Precision Immunology Institute at Mount Sinai is hiring! If you’re a motivated postdoc interested in ovarian cancer- immune system interactions and novel immune therapeutics, come join our group!

Just out! 👉Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0 Society for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer jitc.bmj.com/content/11/10/…

Please join us today at #SITC23 for the Rapid Oral Abstract- Clinical session 205b today at 12:10 PDT Hall C to João Alessi, MD @MLopezdeRodas Michelle Alyssa Tran, PhD and others Society for Immunotherapy of Cancer SITC Early Career Scientist Committee I am looking forward to chairing this session with Allison Betof Warner, MD, PhD

Looking forward to #SITC24!

Honored to present about Oncolytic HSV-1 and Replimune clinical and biomarker data Gustave Roussy

Great team Society for Immunotherapy of Cancer #AACR24 #SITCSRC SITC Early Career Scientist Committee Avery Posey @gulleyj1 Jennifer Guerriero, PhD Stefani Spranger Zachary Cooper, PhD Wungki Park, MD MS Sandra Demaria Dr. Romero & Dr. Ribas AACR

Happening AACR #AACR24 hall GH, beyond immune checkpoint inhibitors #transplant $REPL RP1 onoclytic HSV-1 mono therapy ~35%% ORR in SOT recipients with CSCC and no organ rejection in patients with hepatic, renal and lung transplant

Heading to ASCO #ASC02024 Don’t miss our oral presentations in immune check point inhibitor (PD-1/+/-CTLA-4) failed melanoma and uveal melanoma. Visit replimune.com to learn more about our science and clinical programs.

An informative discussion on recent FDA initiatives including Project Optimus, FrontRunner and Accelerated Approvals. Thanks to Society for Immunotherapy of Cancer IO initiative